Browse ADAM17

Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF16698 Membrane-proximal domain
PF00200 Disintegrin
PF01562 Reprolysin family propeptide
Function

Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2.

> Gene Ontology
 
Biological Process GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0000082 G1/S transition of mitotic cell cycle
GO:0001558 regulation of cell growth
GO:0001666 response to hypoxia
GO:0001776 leukocyte homeostasis
GO:0001819 positive regulation of cytokine production
GO:0002011 morphogenesis of an epithelial sheet
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002262 myeloid cell homeostasis
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002446 neutrophil mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002467 germinal center formation
GO:0002521 leukocyte differentiation
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006509 membrane protein ectodomain proteolysis
GO:0007159 leukocyte cell-cell adhesion
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007176 regulation of epidermal growth factor-activated receptor activity
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007219 Notch signaling pathway
GO:0007220 Notch receptor processing
GO:0007346 regulation of mitotic cell cycle
GO:0010469 regulation of receptor activity
GO:0010818 T cell chemotaxis
GO:0010819 regulation of T cell chemotaxis
GO:0010820 positive regulation of T cell chemotaxis
GO:0016049 cell growth
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0030098 lymphocyte differentiation
GO:0030183 B cell differentiation
GO:0030217 T cell differentiation
GO:0030307 positive regulation of cell growth
GO:0030335 positive regulation of cell migration
GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway
GO:0030512 negative regulation of transforming growth factor beta receptor signaling pathway
GO:0030595 leukocyte chemotaxis
GO:0031293 membrane protein intracellular domain proteolysis
GO:0031657 regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle
GO:0031659 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032642 regulation of chemokine production
GO:0032722 positive regulation of chemokine production
GO:0032844 regulation of homeostatic process
GO:0033023 mast cell homeostasis
GO:0033024 mast cell apoptotic process
GO:0033025 regulation of mast cell apoptotic process
GO:0033028 myeloid cell apoptotic process
GO:0033032 regulation of myeloid cell apoptotic process
GO:0033077 T cell differentiation in thymus
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0033619 membrane protein proteolysis
GO:0033627 cell adhesion mediated by integrin
GO:0033674 positive regulation of kinase activity
GO:0034612 response to tumor necrosis factor
GO:0035313 wound healing, spreading of epidermal cells
GO:0035624 receptor transactivation
GO:0035625 epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway
GO:0036293 response to decreased oxygen levels
GO:0038127 ERBB signaling pathway
GO:0040017 positive regulation of locomotion
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042493 response to drug
GO:0042742 defense response to bacterium
GO:0044319 wound healing, spreading of cells
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045737 positive regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0045741 positive regulation of epidermal growth factor-activated receptor activity
GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
GO:0045787 positive regulation of cell cycle
GO:0045860 positive regulation of protein kinase activity
GO:0045927 positive regulation of growth
GO:0048247 lymphocyte chemotaxis
GO:0048536 spleen development
GO:0048872 homeostasis of number of cells
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050830 defense response to Gram-positive bacterium
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051088 PMA-inducible membrane protein ectodomain proteolysis
GO:0051272 positive regulation of cellular component movement
GO:0055094 response to lipoprotein particle
GO:0055099 response to high density lipoprotein particle
GO:0060326 cell chemotaxis
GO:0061097 regulation of protein tyrosine kinase activity
GO:0061098 positive regulation of protein tyrosine kinase activity
GO:0070482 response to oxygen levels
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071356 cellular response to tumor necrosis factor
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0071593 lymphocyte aggregation
GO:0071594 thymocyte aggregation
GO:0071887 leukocyte apoptotic process
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072676 lymphocyte migration
GO:0072678 T cell migration
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090101 negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0090504 epiboly
GO:0090505 epiboly involved in wound healing
GO:0098542 defense response to other organism
GO:1901184 regulation of ERBB signaling pathway
GO:1901186 positive regulation of ERBB signaling pathway
GO:1901623 regulation of lymphocyte chemotaxis
GO:1901987 regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1902806 regulation of cell cycle G1/S phase transition
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903845 negative regulation of cellular response to transforming growth factor beta stimulus
GO:1903846 positive regulation of cellular response to transforming growth factor beta stimulus
GO:1904029 regulation of cyclin-dependent protein kinase activity
GO:1904031 positive regulation of cyclin-dependent protein kinase activity
GO:2000045 regulation of G1/S transition of mitotic cell cycle
GO:2000106 regulation of leukocyte apoptotic process
GO:2000147 positive regulation of cell motility
GO:2000273 positive regulation of receptor activity
GO:2000401 regulation of lymphocyte migration
GO:2000403 positive regulation of lymphocyte migration
GO:2000404 regulation of T cell migration
GO:2000406 positive regulation of T cell migration
Molecular Function GO:0004175 endopeptidase activity
GO:0004222 metalloendopeptidase activity
GO:0005112 Notch binding
GO:0005126 cytokine receptor binding
GO:0005138 interleukin-6 receptor binding
GO:0005178 integrin binding
GO:0008237 metallopeptidase activity
GO:0017124 SH3 domain binding
GO:0030165 PDZ domain binding
GO:0050839 cell adhesion molecule binding
GO:0070851 growth factor receptor binding
Cellular Component GO:0001726 ruffle
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0015629 actin cytoskeleton
GO:0016324 apical plasma membrane
GO:0030055 cell-substrate junction
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0032587 ruffle membrane
GO:0045121 membrane raft
GO:0045177 apical part of cell
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04330 Notch signaling pathway
Reactome R-HSA-2122948: Activated NOTCH1 Transmits Signal to the Nucleus
R-HSA-1442490: Collagen degradation
R-HSA-2691232: Constitutive Signaling by NOTCH1 HD Domain Mutants
R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-2660826: Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-73887: Death Receptor Signalling
R-HSA-1474228: Degradation of the extracellular matrix
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-1474244: Extracellular matrix organization
R-HSA-982772: Growth hormone receptor signaling
R-HSA-5358346: Hedgehog ligand biogenesis
R-HSA-168256: Immune System
R-HSA-1251985: Nuclear signaling by ERBB4
R-HSA-156988: Receptor-ligand binding initiates the second proteolytic cleavage of Notch receptor
R-HSA-193692: Regulated proteolysis of p75NTR
R-HSA-5362798: Release of Hh-Np from the secreting cell
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-1236394: Signaling by ERBB4
R-HSA-5358351: Signaling by Hedgehog
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
R-HSA-2691230: Signaling by NOTCH1 HD Domain Mutants in Cancer
R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603: Signaling by NOTCH1 in Cancer
R-HSA-2660825: Signaling by NOTCH1 t(7;9)(NOTCH1
R-HSA-166520: Signalling by NGF
R-HSA-75893: TNF signaling
R-HSA-193704: p75 NTR receptor-mediated signalling
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ADAM17 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ADAM17 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23526433Breast Carcinoma; Pancreatic Carcinoma; Prostate CarcinomaInhibit immunity (T cell function)The interaction of the MHC class I-related chain molecules A and B (MICA and MICB) with the corresponding natural killer group 2, member D (NKG2D) receptor triggers cytotoxic effector activity of natural killer cells and certain T-cell subsets and provides a costimulatory signal for cytokine production. Flow cytometry and enzyme-linked immunosorbent assay (ELISA) revealed that all tested tumor cells constitutively expressed MICA and MICB on the cell surface and also released NKG2D ligands into the supernatant. Studies using RNA interference not only revealed a prominent role of ADAM10 and ADAM17 in NKG2D ligand shedding but also a tumor cell-specific role of ADAM10 and/or ADAM17 in shedding of MICA or MICB. These data indicate that the release of NKG2D ligands from individual tumor entities is by far more complex than suggested in previously reported MICA/B transfection systems.
23690482Acute Myeloid LeukemiaInhibit immunity (NK cell function)We determined whether a novel bispecific killer cell engager (BiKE) signaling through CD16 and targeting CD33 could activate NK cells at high potency against acute myelogenous leukemia (AML) targets. Combination treatment with CD16 × 33 BiKE and ADAM17 inhibitor resulted in inhibition of CD16 shedding in NK cells, and enhanced NK cell activation.
24780758Pancreatic AdenocarcinomaInhibit immunityTumor cells from different cancer entities released B7-H6 by ectodomain shedding mediated by the cell surface proteases "a disintegrin and metalloproteases" (ADAM)-10 and ADAM-17, as demonstrated through the use of pharmacologic inhibitors or siRNA-mediated gene attenuation. Inhibiting this proteolytic shedding process increased the levels of B7-H6 expressed on the surface of tumor cells, enhancing NKp30-mediated activation of NK cells.
29308299Metastatic Non-Squamous Non-Small Cell Lung CarcinomaInhibit immunity (NK cell function)Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Similar results were obtained upon exposure of tumor cells to platelet-releasate and can be attributed to the sheddases ADAM10 and ADAM17 that are detectable on the platelet surface and in releasate following activation and at higher levels on platelets of patients with metastasized lung cancer compared with healthy controls.
24327582GlioblastomaInhibit immunityHere,we show that ADAM10 and ADAM17 are expressed on the cell surface of GIC and contribute to an immunosuppressive phenotype by cleavage of ULBP2. And treatment with ADAM10 and ADAM17 specific inhibitors leads to enhanced immunerecognition of GIC by natural killer cells. Therefore, ADAM10 and ADAM17 constitute suitable targets to boost an immune response against GIC.
29873070Hepatocellular CarcinomaInhibit immunityNatural killer cells eliminate various cancer cells, including HCC, by suppressing MICA shedding. ADAM17 knockdown reduced sMICA levels and increased membrane-bound MICA (mMICA) expression in HCC cells.
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ADAM17 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ADAM17 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0770.785
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0550.974
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0990.93
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2470.412
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4980.806
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.0740.978
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1790.646
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0240.988
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.3920.813
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2120.839
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1610.404
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0310.66
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ADAM17 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ADAM17. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ADAM17. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ADAM17.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ADAM17. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ADAM17 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ADAM17 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolADAM17
NameADAM metallopeptidase domain 17
Aliases cSVP; CD156B; TACE; tumor necrosis factor, alpha, converting enzyme; NISBD; NISBD1; TNF-alpha convertase; TN ......
Chromosomal Location2p25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ADAM17 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting ADAM17.
ID Name Drug Type Targets #Targets
DB06943(3S)-1-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}pyrrolidine-3-thiolSmall MoleculeADAM171
DB070793-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}propane-1-thiolSmall MoleculeADAM171
DB071214-({4-[(4-AMINOBUT-2-YNYL)OXY]PHENYL}SULFONYL)-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDESmall MoleculeADAM171
DB07145(2R)-N-HYDROXY-2-[(3S)-3-METHYL-3-{4-[(2-METHYLQUINOLIN-4-YL)METHOXY]PHENYL}-2-OXOPYRROLIDIN-1-YL]PROPANAMIDESmall MoleculeADAM171
DB07147methyl (1R,2S)-2-(hydroxycarbamoyl)-1-{4-[(2-methylquinolin-4-yl)methoxy]benzyl}cyclopropanecarboxylateSmall MoleculeADAM171
DB07189(1S,3R,6S)-4-oxo-6-{4-[(2-phenylquinolin-4-yl)methoxy]phenyl}-5-azaspiro[2.4]heptane-1-carboxylic acidSmall MoleculeADAM171
DB07233N-{[4-(but-2-yn-1-yloxy)phenyl]sulfonyl}-5-methyl-D-tryptophanSmall MoleculeADAM171
DB07964(3S)-4-{[4-(BUT-2-YNYLOXY)PHENYL]SULFONYL}-N-HYDROXY-2,2-DIMETHYLTHIOMORPHOLINE-3-CARBOXAMIDESmall MoleculeADAM171